ArticleBMJ paediatrics open2026
Examining the effect of newborn feeding method on postnatal length of stay and healthcare utilisation among Neonates With In-utero SSRI Exposure (NeoWISE): a retrospective cohort study.
Article in BMJ paediatrics open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionUp to 30% of in-utero selective serotonin reuptake inhibitor (SSRI)-exposed newborns experience withdrawal and up to 60% experience behavioural impacts. Breastfeeding may offer benefits from skin-to-skin contact and transfer of SSRIs through breastmilk. Limited data are available on healthcare utilisation of these newborns beyond neonatal intensive care unit admission. We aimed to identify whether newborn feeding method affected healthcare utilisation in the first 30 days of postnatal life among
methodsThis retrospective cohort study included newborns born in Ontario hospitals between 1 April 2012 and 31 March 2020 to beneficiaries of the Ontario Drug Benefit Program who filled at least one SSRI prenatal prescription. Administrative health and birth registry data were used. Newborn feeding methods were available from birth to hospital discharge. Outcomes were postnatal length of stay (LOS), emergency department visit(s) and hospital readmission within the first 30 days of life. Adjusted linear regression models using inverse probability of treatment weights for feeding method were conducted.
resultsThe cohort included a total of 5079 NeoWISE participants, with 3321 (65.4%) exclusively breastfed. Formula-fed infants were more likely to have older mothers with an urban residence, lower income quintile, prior live birth, who smoked at delivery and to be born via caesarean delivery; these imbalances were balanced after propensity score weighting. Exclusively breastfed newborns were significantly less likely to have postnatal LOS ≥3 days (11.6% vs 16.3%) (adjusted relative risk (adjRR) 0.84, 95% CI 0.72 to 0.97), but more likely to have emergency department visit (adjRR 1.42, 95% CI 1.03 to 1.97) and hospital readmission (adjRR 1.78, 95% CI 1.21 to 2.62) compared with formula-fed newborns, primarily due to jaundice.
conclusionWomen taking SSRI medication during pregnancy should receive anticipatory guidance about newborn feeding effectiveness, signs of jaundice and when to seek healthcare after birth. In-hospital feeding method was associated with emergency department visits and hospital readmission among NeoWISE. Breastfeeding cessation was not measured and could have affected estimated associations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.